Climb Bio reports first patient dosed in Phase 2 trial

Climb Bio, Inc. reports that its collaborator Beijing Mabworks Biotech Co., Ltd. has dosed the first patient with immunoglobulin A nephropathy in a Phase 2 clinical trial in China.

Rhea-AI Filing Summary

Climb Bio, Inc. reports that its collaborator Beijing Mabworks Biotech Co., Ltd. has dosed the first patient with immunoglobulin A nephropathy in a Phase 2 clinical trial in China. The study is being conducted under a collaboration between the two companies focused on this kidney disease indication.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Terms

immunoglobulin A nephropathy, Phase 2 clinical trial, Emerging growth company

3 terms

immunoglobulin A nephropathy medical

"announced the dosing of the first patient with immunoglobulin A nephropathy"

A kidney disease in which a specific antibody called IgA builds up in the kidney’s tiny filters, causing inflammation and gradual loss of filtering function — like grit clogging a coffee filter. It matters to investors because the condition can lead to long-term treatment needs (medications, monitoring, dialysis, transplants) and is the focus of drug trials and regulatory review, so progress or setbacks directly affect healthcare spending, company revenues and insurer liabilities.

Phase 2 clinical trial medical

"in a Phase 2 clinical trial in China, which is being conducted"

A phase 2 clinical trial is a research study that tests a new medical treatment or drug to see if it is effective and safe for a specific condition. It involves a larger group of people than earlier trials and helps determine whether the treatment should move forward to more extensive testing. For investors, successful phase 2 results can signal potential for future approval and commercial success, while setbacks may indicate challenges ahead.

Emerging growth company regulatory

"Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Climb Bio, Inc. (CLYM) disclose in its latest 8-K?

Climb Bio, Inc. disclosed that collaborator Beijing Mabworks Biotech Co., Ltd. has dosed the first patient with immunoglobulin A nephropathy in a Phase 2 clinical trial in China, conducted under a collaboration between the two companies.

What clinical milestone involving Climb Bio, Inc. (CLYM) was reached in China?

The first patient with immunoglobulin A nephropathy was dosed in a Phase 2 clinical trial in China. This trial is being conducted by Beijing Mabworks Biotech Co., Ltd. in collaboration with Climb Bio, Inc.

Which partner is collaborating with Climb Bio, Inc. (CLYM) on the Phase 2 trial?

Climb Bio, Inc. is collaborating with Beijing Mabworks Biotech Co., Ltd. on a Phase 2 clinical trial in China that has now dosed its first patient with immunoglobulin A nephropathy under the companies’ collaboration.

What disease is targeted in the Phase 2 trial involving Climb Bio, Inc. (CLYM)?

The Phase 2 clinical trial targets immunoglobulin A nephropathy, a kidney disease. Beijing Mabworks Biotech Co., Ltd. announced dosing of the first patient in China, with the trial conducted in collaboration with Climb Bio, Inc.

Where is Climb Bio, Inc. (CLYM) conducting its collaborative Phase 2 trial?

The collaborative Phase 2 clinical trial involving Climb Bio, Inc. is being conducted in China. Beijing Mabworks Biotech Co., Ltd. announced dosing of the first patient with immunoglobulin A nephropathy in this study.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 08:31 AM Accepted by SEC EDGAR 08/14/2026 - 08:30 AM Learn about SEC filing dates

false 0001768446 0001768446 2026-08-13 2026-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2026

CLIMB BIO, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-40708		83-2273741
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

20 William Street, Suite 145
Wellesley Hills, Massachusetts		02481
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (866) 857-2596

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CLYM		The Nasdaq Stock Market LLC (The Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On August 13, 2026, Beijing Mabworks Biotech Co., Ltd. announced the dosing of the first patient with immunoglobulin A nephropathy in a Phase 2 clinical trial in China, which is being conducted in collaboration with Climb Bio, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Climb Bio, Inc.
Date: August 14, 2026				By:		/s/ Aoife Brennan
						Aoife Brennan, M.B., Ch.B.
						President and Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 18.3 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.4 KB